Pulse Biosciences (PLSE) Stock Forecast & Price Target

Pulse Biosciences is attractive because its nsPFA platform is meaningfully differentiated, with nanosecond, non-thermal energy that has produced strong feasibility outcomes across 141 patients, including 100% six-month procedural success, 96.2% 12-month success, 90% one-year freedom from AF/AFL/AT, and a 1.7% primary safety event rate. Its commercial case is strengthened by best-in-class procedure efficiency, broad patent protection with more than 250 issued patents, and a pipeline spanning catheter, surgical, and soft-tissue ablation across large, underpenetrated markets. The company also has a solid balance sheet with $101.6M in cash and no debt as of June 30, 2026, while rapid NANOPULSE-AF enrollment and partnership optionality increase the likelihood of a major catalyst.

Pulse Biosciences is a pre-revenue, unprofitable company whose investment case is dominated by binary clinical and regulatory outcomes, with NANOPULSE-AF and NANOCLAMP-AF still needed to prove safety, efficacy, and FDA viability. The bearish view is reinforced by execution risk from potential pivotal trial delays, the possibility that feasibility results do not translate into the U.S. population, and the fact that disappointing outcomes could severely weaken commercialization prospects. Financially, the company ended 2Q26 with $102M of cash but burned $54M in 2025 and $33M in 1H26, so continued losses and likely future equity raises create meaningful dilution risk, especially without a secured commercial partner.